From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss.

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

A recent analysis of adverse drug reactions by Indian Pharmacopoeia Commission revealed that combinations of beta-blockers ...

Inverse psoriasis, which causes painful lesions on sensitive skin folds, can be hard to treat. Find out more about this type of psoriasis.

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines offset slumping Stelara sales.

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid and advanced skin cancer. This FDA recap highlights recent approvals in April ...